-
1
المؤلفون: Xiaohui Pan, Bo Yang, Hongjie Guo, Shuyuan Cheng, Xi Chen, Ling Ding, Qiaojun He, Wenxin Zhang
المصدر: Acta Pharmaceutica Sinica B, Vol 10, Iss 5, Pp 723-733 (2020)
Acta Pharmaceutica Sinica. Bمصطلحات موضوعية: TIM-3, T cell immunoglobulin and mucin domain 3, H3K27me3, tri-methylation of lysine 27 on histone H3, MDSCs, myeloid-derived suppressor cells, medicine.medical_treatment, Review, TAA, tumor-associated antigen, DC, dendritic cell, 0302 clinical medicine, EZH2, enhancer of zeste homolog 2, LAG-3, lymphocyte activation gene-3, CTLA-4, cytotoxic T lymphocyte antigen 4, Medicine, BETi, bromodomain and extra-terminal motif inhibitors, General Pharmacology, Toxicology and Pharmaceutics, FOXP3, forkhead box P3, HDACi, histone deacetylase inhibitor, Cancer, 0303 health sciences, ACE1, angiotensin converting enzyme, CLL, chronic lymphocytic leukemia, biology, IDO, indoleamine 2,3-dioxygenase, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Tregs, regulatory T cells, PD-L1/PD-1 blockade, CCL22 (MDC), macrophage-derived chemokine, Immunotherapy, TET2, ten-eleven translocation 2, CTLs, cytotoxic T lymphocytes, FDA, U. S. Food and Drug Administration, PD-L1, programmed cell death ligand 1, T cell, CTA, cancer testis antigen, Immune cycle, TIL, tumor infiltrating lymphocytes, Epigenetic regulation, OS, overall survival, 03 medical and health sciences, Immune system, Antigen, PD-L1, TH-1, T helper type 1, DNMT1, DNA methyltransferase 1, MHC, major histocompatibility complex, CX3CL1, C-X3-C motif chemokine ligand 1, IFN-γ, interferon-gamma, 030304 developmental biology, business.industry, lcsh:RM1-950, biochemical phenomena, metabolism, and nutrition, medicine.disease, CXCL, CXC chemokine ligand, Blockade, lcsh:Therapeutics. Pharmacology, APC, antigen-presenting cell, UHRF1, ubiquitin-like PHD and RING finger domain-containing 1, 5-AzaC, 5-azacitidine, ACP1, human red cell acid phosphatase, biology.protein, Cancer research, bacteria, DNMTi, DNA methyltransferase inhibitors, PD-1, programmed cell death 1, business, PRC2, polycomb repressive complex 2
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1ca7b0479f6fea7a89a3e1eb06905c5Test
https://doi.org/10.1016/j.apsb.2019.09.006Test -
2
المؤلفون: Alberto Pavan, Filippo de Marinis, Laura Bonanno, Antonio Passaro, Ilaria Attili, Pierfranco Conte
المصدر: Critical Reviews in Oncology/Hematology. 119:30-39
مصطلحات موضوعية: PD-L1, 0301 basic medicine, Oncology, medicine.medical_specialty, Lung Neoplasms, medicine.medical_treatment, Programmed Cell Death 1 Receptor, non-small cell lung cancer (NSCLC), Disease, B7-H1 Antigen, IDO, 03 medical and health sciences, 0302 clinical medicine, LAG-3, Carcinoma, Non-Small-Cell Lung, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Animals, Humans, Medicine, CTLA-4 Antigen, Lung cancer, Antiangiogenic treatment, CTLA-4, Combination treatment, Immune checkpoint, Tumor microenvironment, biology, business.industry, Antibodies, Monoclonal, Hematology, medicine.disease, Radiation therapy, 030104 developmental biology, 030220 oncology & carcinogenesis, Immunology, biology.protein, Tumor Escape, Immunotherapy, business
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1bc111800f5ade8f2fadbfbd81d2cc88Test
https://doi.org/10.1016/j.critrevonc.2017.09.007Test